We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

29 hedge funds and large institutions have $12M invested in Hepion Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,515% more capital invested

Capital invested by funds: $741K → $12M (+$11.2M)

283% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 6

142% more funds holding

Funds holding: 12 → 29 (+17)

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

17% more call options, than puts

Call options by funds: $657K | Put options by funds: $562K

Holders
29
Holders Change
+17
Holders Change %
+141.67%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
4
Reduced
2
Closed
6
Calls
$657K
Puts
$562K
Net Calls
+$95K
Net Calls Change
+$137K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$4.48M
2
BlackRock
BlackRock
New York
+$2.94M
3
Renaissance Technologies
Renaissance Technologies
New York
+$853K
4
WVP
Worth Venture Partners
New Jersey
+$606K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$485K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$148K
2
Bank of America
Bank of America
North Carolina
-$85.5K
3
SFI
Susquehanna Fundamental Investments
Pennsylvania
-$48K
4
ECM
ExodusPoint Capital Management
New York
-$36K
5
Citadel Advisors
Citadel Advisors
Florida
-$23.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$3.79M +$4.48M +1,729 New
BlackRock
2
BlackRock
New York
$2.62M +$2.94M +1,133 +1,857%
ACM
3
AIGH Capital Management
Maryland
$2.02M +$2.39M +923 New
Renaissance Technologies
4
Renaissance Technologies
New York
$721K +$853K +329 New
WVP
5
Worth Venture Partners
New Jersey
$512K +$606K +234 New
Geode Capital Management
6
Geode Capital Management
Massachusetts
$443K +$485K +187 +1,169%
PCM
7
Perkins Capital Management
Minnesota
$329K +$389K +150 New
Squarepoint
8
Squarepoint
New York
$245K +$249K +96 +600%
SSA
9
Schonfeld Strategic Advisors
New York
$208K +$246K +95 New
GCP
10
GSA Capital Partners
United Kingdom
$195K +$231K +89 New
PAM
11
Premier Asset Management
Illinois
$153K +$181K +70 New
Northern Trust
12
Northern Trust
Illinois
$139K +$163K +63 New
ZCA
13
Zeke Capital Advisors
Pennsylvania
$110K +$130K +50 New
Bank of New York Mellon
14
Bank of New York Mellon
New York
$90K +$106K +41 New
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$88K +$104K +40 New
PFS
16
Prospera Financial Services
Texas
$86K +$101K +39 New
ACG
17
Allen Capital Group
Nebraska
$52K +$62.2K +24 New
OCAM
18
Onex Canada Asset Management
Ontario, Canada
$44K +$51.8K +20 New
Citadel Advisors
19
Citadel Advisors
Florida
$24K -$23.3K -9 -45%
Commonwealth Equity Services
20
Commonwealth Equity Services
Massachusetts
$22K +$25.9K +10 New
Bank Julius Baer & Co
21
Bank Julius Baer & Co
Switzerland
$18K +$20.7K +8 New
SFS
22
Sowell Financial Services
Arkansas
$16K +$18.1K +7 New
Morgan Stanley
23
Morgan Stanley
New York
$14K +$15.5K +6 New
IA
24
IFP Advisors
Florida
$11K +$13K +5 New
Group One Trading
25
Group One Trading
Illinois
$10K +$13K +5 New
1
2

HEPA Hedge Fund Activity: Q4 2020 in Review

29 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q4 2020, worth a combined $12M — up 1,515% from $741K a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new HEPA positions and 6 closed out — a net gain of 17 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $4.48M. The largest seller was Sabby Management, exiting entirely with an estimated $148K sold.

  • 29 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q4 2020, up from 12 in Q3 2020.
  • Funds reported $12M of Hepion Pharmaceuticals stock for Q4 2020, up 1,515% quarter-over-quarter.
  • 23 funds opened new Hepion Pharmaceuticals positions in Q4 2020 and 6 closed out, a net change of +17 holders.
  • The largest Hepion Pharmaceuticals buyer in Q4 2020 was Vanguard Group, an estimated $4.48M added.
  • The largest Hepion Pharmaceuticals seller in Q4 2020 was Sabby Management, an estimated $148K sold.

Based on aggregated 13F filings for Q4 2020.